Developer docs
API playgroundTry for free, no card

Search company profiles

BioCanRx

Full company profile

uuid0002vf6

Namestring
BioCanRx
Legal namestring
BioCanRx
Websiteurl
biocanrx.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

BioCanRx is a Canadian not-for-profit research network founded in 2014 and hosted by the Ottawa Hospital Research Institute, dedicated to translating cancer immunotherapy discoveries into clinical trials. Its core technical scope spans CAR T-cell therapies (notably the CLIC-1901 CD19-targeting product manufactured domestically via a point-of-care network spanning Vancouver, Victoria, and Ottawa), oncolytic viral immunotherapies (including Maraba virus and Ad-MG1-MAGEA3 platforms), monoclonal antibodies (via the Immunotherapy Monoclonal Antibody Platform, IMAP), RNA-based vaccines, tumor-infiltrating lymphocyte therapy, and radiolabeled antibody therapies. The network operates four core facilities — the GMP-compliant Biotherapeutics Manufacturing Centre (BMC), IMAP at IRCM, the Molecular and Cellular Immunology Core (MCIC) supporting 50–60 projects annually, and IRICoR for commercialization — providing researchers with biomanufacturing, analytics, and drug discovery infrastructure that meets ICH Q10, Health Canada, and FDA standards.

The organization funds translational research through competitive peer-reviewed programs (Catalyst, Enabling, Clinical Trials, and Clinical, Social & Economic Impact studies), with the 2024–2025 cycle alone supporting 20 research projects and four core facilities. BioCanRx's revenue model is dominated by federal government funding — primarily through the Strategic Science Fund (~$38M awarded in May 2024, with a $12.5M tranche in April 2025) — supplemented by partner and industry co-funding from organizations such as the Ontario Institute for Cancer Research, Mitacs, the Terry Fox Research Institute, the Canadian Cancer Society, and the Cancer Research Society. Customer segments are horizontal: academic researchers and clinician-scientists at more than 10 Canadian universities and research hospitals are the primary users of funding and core facilities; cancer patients and advocates engage through the Cancer Stakeholder Alliance and Learning Institute; industry partners (including biotech spinouts such as Turnstone Biologics and Virica Biotech) access manufacturing capacity and technology transfer; and trainees participate via CanPRIME biomanufacturing micro-credentials, the Summer Studentship program, and the HQP Association. The go-to-market motion is community-led, with the annual Summit for Cancer Immunotherapy (Summit4CI, 300+ attendees) serving as the principal convening and knowledge-mobilization channel.

Short descriptiontext

BioCanRx is a Canadian not-for-profit research network founded in 2014 that funds and accelerates the translation of cancer immunotherapy discoveries — including CAR T, oncolytic viruses, mAbs, and RNA vaccines — into clinical trials through competitive grants, GMP biomanufacturing facilities, training programs, and a national network of academic, clinical, and industry partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersOttawa, Canada
HQ citystring
Ottawa
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cancer immunotherapy research, translational research funding, CAR T-cell manufacturing, biotherapeutics manufacturing, clinical trial support
Industry4 codes
PRIMARYHLAAAKAF
Process Development & Tech Transfer Services (upstream/downstream)
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cancer Immunotherapy Research Network
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Federal Government Research Funding
TypeSubscription Recurring
Description

BioCanRx receives federal funding primarily through the Government of Canada's Strategic Science Fund to support translational cancer immunotherapy research, clinical trials, core facilities, and training programs. This is the dominant revenue stream enabling network operations.

biocanrx.com
2Partner and Industry Contributions
TypeManaged Services
Description

Co-funding and in-kind contributions from industry partners, provincial governments, and charitable organizations supplement federal funding to support specific projects, core facilities, and training initiatives.

biocanrx.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 5 records shown
1Summit4CI
Description

Annual Summit for Cancer Immunotherapy bringing together scientists, clinicians, students, industry, patient groups, and government representatives.

biocanrx.com
+4 more records
Core offering1 text field

BioCanRx is Canada's Immunotherapy Network — a not-for-profit research network that funds and actively supports the translation, manufacture, and adoption of cancer immunotherapies. The organization operates as a network-based platform providing competitive research funding, access to GMP biomanufacturing core facilities, training programs, and the CLIC Network for made-in-Canada CAR T-cell therapies, with the goal of moving promising discoveries from the lab into clinical trials.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Over 40 made-in-Canada clinical trials supported through the network
+4 more records
Product overview1 text field

BioCanRx is Canada’s Immunotherapy Network — a research funding and support organization that operates as a platform of interconnected programs to accelerate cancer immunotherapy from discovery to clinical trials. The organization provides competitive translational research funding (Catalyst, Enabling, Clinical Trial, and CSEI programs), supports access to four core biomanufacturing and immunology facilities (IMAP, BMC, MCIC, IRICoR), operates the CanPRIME biomanufacturing training program, manages the annual Summit4CI conference and Learning Institute, and funds the made-in-Canada CLIC-1901 CAR T cell therapy. BioCanRx Summer Studentships engage undergraduate researchers, while patient resources provide immunotherapy education. The network connects academic researchers with manufacturing facilities, clinical trial infrastructure, and commercialization expertise to translate discoveries into treatments.

Product and service8 records
1BioCanRx Research Funding Programs
CategoryResearch Funding
2CLIC-1901 CAR T Cell Therapy
CategoryCell Therapy
3Core Facility Access
CategoryBiomanufacturing and Research Services
4CanPRIME Biomanufacturing Training Program
CategoryWorkforce Training
5Summit4CI (Summit for Cancer Immunotherapy)
CategoryConference and Convening
6Learning Institute
CategoryEducation and Patient Engagement
7BioCanRx Summer Studentships
CategoryTrainee Programs
8CLIC Network
CategoryClinical Trial and Manufacturing Network
Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership28 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-22
Description

Lead partner in a $25-million multi-partner national clinical cancer research program. BioCanRx is one of several cancer research funders collaborating to support investigator-initiated clinical trials for rare, underserved, and low-survival cancers across Canada. The program provides grants of up to $2 million over five years.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-22
Description

Co-funder of the $25-million national clinical cancer research program supporting investigator-initiated clinical trials for rare and underserved cancers.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-22
Description

Co-funder of the $25-million national clinical cancer research program. BioCanRx and TFRI have a history of co-funding translational cancer research initiatives.

4Lotte & John Hecht Memorial Foundation
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-04-22
Description

Funder of the $25-million multi-partner clinical cancer research program.

finance.yahoo.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-04-22
Description

Funder of the $25-million multi-partner clinical cancer research program.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-04-22
Description

Partner funder of the $25-million multi-partner clinical cancer research program.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-04-22
Description

Partner funder of the $25-million multi-partner clinical cancer research program.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-04-22
Description

Partner funder of the $25-million multi-partner clinical cancer research program.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-04-22
Description

Partner funder of the $25-million multi-partner clinical cancer research program.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

BioCanRx is hosted by the Ottawa Hospital Research Institute. OHRI provides institutional infrastructure including the Biotherapeutics Manufacturing Centre, a world-class GMP facility with over 17 years of experience supporting BioCanRx projects.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Network partner providing the Conconi Family Immunotherapy Lab for CAR T cell manufacturing and the Genome Sciences Centre for plasmid manufacturing. Also hosts the Molecular and Cellular Immunology Core (MCIC).

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Network partner providing research facilities including the McMaster Immunology Research Centre for recombinant virus production. Home to key BioCanRx investigators such as Dr. Brian Lichty.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Network partner institution with researchers engaged in BioCanRx-funded projects in cancer immunotherapy.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Network partner and host university for BioCanRx-hosted OHRI. Key research collaborator in CAR T and viral immunotherapy programs.

15University of British Columbia
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Network partner institution with researchers at UBC and affiliated institutions contributing to BioCanRx-funded research.

biocanrx.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Network partner providing pediatric clinical trial sites for CAR T therapy. Partner in the $25-million multi-partner clinical research program.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Network partner institution with researchers engaged in BioCanRx-funded cancer immunotherapy projects.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Network partner institution contributing researchers and clinical expertise to BioCanRx-funded projects.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Network partner institution collaborating on BioCanRx-funded cancer immunotherapy research.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Network partner hosting Princess Margaret Cancer Centre, a major adult clinical trial site for BioCanRx-funded CAR T trials. Dr. Marcus Butler leads Canadian-developed CAR T-cell therapy trials.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Hosts the Immunotherapy Monoclonal Antibody Platform (IMAP), a first-of-its-kind academic mAb facility in Canada established in 2020. Led by Dr. André Veillette, IMAP provides access to cutting-edge platforms for accelerating monoclonal antibody development for cancer treatment.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

National leader in drug discovery and commercialization at Université de Montréal. Through a BioCanRx agreement, projects access IRICoR's scientific operations, IP strategies, business development, and industry collaboration support to move assets toward commercialization.

23Turnstone Biologics Inc.
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Ottawa-based biotech spinout from BioCanRx network research (Bell, Lichty, Stojdl). BioCanRx supported early development of Turnstone's oncolytic viral immunotherapy platform, including the Ad-MG1-MAGEA3 product. Turnstone subsequently partnered with AbbVie in a major global collaboration. Recognized as one of the top 15 biotech start-ups in the world (FierceBiotech's 2017 Fierce 15).

biocanrx.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Ottawa-based biotech company that received timely BioCanRx investment to develop biomanufacturing tools that decrease the cost of manufacturing vaccines and biotherapeutics. CEO Dr. Jean-Simon Diallo is a network investigator at OHRI. Virica's innovations have enhanced biomanufacturing efficiency for network partners and have global commercialization potential.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Indigenous-led charity providing mentorship for Indigenous students who receive BioCanRx Summer Studentships through the Rivers to Success program, offering one-on-one and group guidance from Indigenous peers and role models.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partner with BioCanRx and the University of Ottawa in developing a micro-credential in good manufacturing practices (GMP) for biomanufacturing. Algonquin's college-level training complements university-level offerings in the CanPRIME program.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

National organization providing hands-on science outreach. BioCanRx partners with Let's Talk Science to deliver cancer immunotherapy lessons, lab tours, and workshops in Canadian high schools, engaging over 10,000 students to date.

28Alberta Cell Therapy Manufacturing Facility (ACTM)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

GMP cell manufacturing facility in Edmonton that received technology transfer from BioCanRx network researchers (Levings Lab) for thymic Treg manufacturing through the Lab Exchange program.

biocanrx.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

PICI is a US-based non-profit that funds and coordinates cancer immunotherapy research across leading academic centers, with a strong focus on translational science and clinical trials. PICI is BioCanRx's closest functional analog as a multi-institutional cancer immunotherapy research network.

TypeDirect peer
Description

CRI is a US non-profit that has funded immunology and cancer immunotherapy research for decades, supporting investigator-initiated translational grants and clinical trials. Like BioCanRx, CRI bridges academic discovery and clinical application in immuno-oncology.

TypeDirect peer
Description

SU2C is a major US charitable funder of translational cancer research, including multi-institutional "Dream Teams" focused on specific cancer types and modalities. Its model of funding collaborative translational teams closely parallels BioCanRx's network approach.

TypeDirect peer
Description

Ludwig is an international non-profit cancer research organization that operates across multiple centers, with significant translational and immunotherapy programs. It is comparable as a globally distributed, academically anchored cancer research network.

TypeDirect peer
Description

TFRI is a Canadian non-profit that funds pan-Canadian translational cancer research, including the recently co-funded $25M multi-partner clinical research program with BioCanRx. TFRI is both a peer and an active partner.

TypeOthers
Description

SITC is a professional society that advances cancer immunotherapy through education, conferences, and scientific exchange. While not a funder like BioCanRx, SITC operates similar community/convening functions in immuno-oncology (e.g., annual meetings akin to Summit4CI).

TypeEmerging player
Description

Cellares is an emerging cell therapy manufacturing automation company whose Cell Shuttle platform competes with the closed/automated point-of-care manufacturing concept that BioCanRx's CLIC network has built around. Both target decentralized, scalable CAR T production.

TypeBroad incumbent
Description

Lonza is a major global CDMO with extensive cell and gene therapy manufacturing capacity, including GMP viral vector and cell therapy production. As BioCanRx scales its BMC and CLIC manufacturing, Lonza is a global incumbent competitor for outsourced GMP services.

TypeDirect peer
Description

CRS is a Canadian non-profit cancer research funder, lead partner in the $25M multi-partner clinical research program with BioCanRx. It is comparable as a Canadian cancer research funding organization, though with a broader scope beyond immunotherapy.

TypeOthers
Description

OHRI is the host institution for BioCanRx and provides core infrastructure including the Biotherapeutics Manufacturing Centre. As BioCanRx's institutional home and primary research partner, OHRI is functionally co-located rather than a competing entity.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers11 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BioCanRx

Cancer Immunotherapy Research Networkbiocanrx.com

BioCanRx is a Canadian not-for-profit research network founded in 2014 that funds and accelerates the translation of cancer immunotherapy discoveries — including CAR T, oncolytic viruses, mAbs, and RNA vaccines — into clinical trials through competitive grants, GMP biomanufacturing facilities, training programs, and a national network of academic, clinical, and industry partners.

What BioCanRx does

BioCanRx is a Canadian not-for-profit research network founded in 2014 and hosted by the Ottawa Hospital Research Institute, dedicated to translating cancer immunotherapy discoveries into clinical trials. Its core technical scope spans CAR T-cell therapies (notably the CLIC-1901 CD19-targeting product manufactured domestically via a point-of-care network spanning Vancouver, Victoria, and Ottawa), oncolytic viral immunotherapies (including Maraba virus and Ad-MG1-MAGEA3 platforms), monoclonal antibodies (via the Immunotherapy Monoclonal Antibody Platform, IMAP), RNA-based vaccines, tumor-infiltrating lymphocyte therapy, and radiolabeled antibody therapies. The network operates four core facilities — the GMP-compliant Biotherapeutics Manufacturing Centre (BMC), IMAP at IRCM, the Molecular and Cellular Immunology Core (MCIC) supporting 50–60 projects annually, and IRICoR for commercialization — providing researchers with biomanufacturing, analytics, and drug discovery infrastructure that meets ICH Q10, Health Canada, and FDA standards.

The organization funds translational research through competitive peer-reviewed programs (Catalyst, Enabling, Clinical Trials, and Clinical, Social & Economic Impact studies), with the 2024–2025 cycle alone supporting 20 research projects and four core facilities. BioCanRx's revenue model is dominated by federal government funding — primarily through the Strategic Science Fund (~$38M awarded in May 2024, with a $12.5M tranche in April 2025) — supplemented by partner and industry co-funding from organizations such as the Ontario Institute for Cancer Research, Mitacs, the Terry Fox Research Institute, the Canadian Cancer Society, and the Cancer Research Society. Customer segments are horizontal: academic researchers and clinician-scientists at more than 10 Canadian universities and research hospitals are the primary users of funding and core facilities; cancer patients and advocates engage through the Cancer Stakeholder Alliance and Learning Institute; industry partners (including biotech spinouts such as Turnstone Biologics and Virica Biotech) access manufacturing capacity and technology transfer; and trainees participate via CanPRIME biomanufacturing micro-credentials, the Summer Studentship program, and the HQP Association. The go-to-market motion is community-led, with the annual Summit for Cancer Immunotherapy (Summit4CI, 300+ attendees) serving as the principal convening and knowledge-mobilization channel.

BioCanRx firmographics

Firmographics
Name
BioCanRx
Legal name
BioCanRx
Website
https://biocanrx.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
BioCanRx is a Canadian not-for-profit research network founded in 2014 that funds and accelerates the translation of cancer immunotherapy discoveries — including CAR T, oncolytic viruses, mAbs, and RNA vaccines — into clinical trials through competitive grants, GMP biomanufacturing facilities, training programs, and a national network of academic, clinical, and industry partners.
Ownership category
akta.pro rank

BioCanRx industry classification

Industry
Product category
Cancer Immunotherapy Research Network
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAKAF
Process Development & Tech Transfer Services (upstream/downstream)
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

Keywords

  • Cancer immunotherapy research
  • Translational research funding
  • CAR T-cell manufacturing
  • Biotherapeutics manufacturing
  • Clinical trial support

Where BioCanRx is headquartered

Location

Headquarters

HQ city
Ottawa
HQ country
Canada
HQ region
North America

Offices2 records

Markets served

BioCanRx business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Federal Government Research Funding: BioCanRx receives federal funding primarily through the Government of Canada's Strategic Science Fund to support translational cancer immunotherapy research, clinical trials, core facilities, and training programs. This is the dominant revenue stream enabling network operations.
  2. Partner and Industry Contributions: Co-funding and in-kind contributions from industry partners, provincial governments, and charitable organizations supplement federal funding to support specific projects, core facilities, and training initiatives.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels8 records

BioCanRx product offering

Product offering

Core offering

BioCanRx is Canada's Immunotherapy Network — a not-for-profit research network that funds and actively supports the translation, manufacture, and adoption of cancer immunotherapies. The organization operates as a network-based platform providing competitive research funding, access to GMP biomanufacturing core facilities, training programs, and the CLIC Network for made-in-Canada CAR T-cell therapies, with the goal of moving promising discoveries from the lab into clinical trials.

Product overview

BioCanRx is Canada’s Immunotherapy Network — a research funding and support organization that operates as a platform of interconnected programs to accelerate cancer immunotherapy from discovery to clinical trials. The organization provides competitive translational research funding (Catalyst, Enabling, Clinical Trial, and CSEI programs), supports access to four core biomanufacturing and immunology facilities (IMAP, BMC, MCIC, IRICoR), operates the CanPRIME biomanufacturing training program, manages the annual Summit4CI conference and Learning Institute, and funds the made-in-Canada CLIC-1901 CAR T cell therapy. BioCanRx Summer Studentships engage undergraduate researchers, while patient resources provide immunotherapy education. The network connects academic researchers with manufacturing facilities, clinical trial infrastructure, and commercialization expertise to translate discoveries into treatments.

Differentiator

Problem solved

Functional benefit

Brands

  • Summit4CI: Annual Summit for Cancer Immunotherapy bringing together scientists, clinicians, students, industry, patient groups, and government representatives.
  • CLIC Network
  • CanPRIME
  • Learning Institute
  • Summer Studentship Program

Products and services

  • BioCanRx Research Funding Programs
  • CLIC-1901 CAR T Cell Therapy
  • Core Facility Access
  • CanPRIME Biomanufacturing Training Program
  • Summit4CI (Summit for Cancer Immunotherapy)
  • Learning Institute
  • BioCanRx Summer Studentships
  • CLIC Network

Quantifiable outcome

  • Over 40 made-in-Canada clinical trials supported through the network
  • +4 more outcomes

Companies that use BioCanRx

Customer profile

Named customers11 records

Segments4 records

Ideal customer profiles4 records

BioCanRx technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

BioCanRx partnerships and signals

Strategic signal

Partnerships

28 partnerships are on record, tiered core and minor.

  • Cancer Research SocietycoreStrategic or Co-development Partner · 22 April 2026Lead partner in a $25-million multi-partner national clinical cancer research program. BioCanRx is one of several cancer research funders collaborating to support investigator-initiated clinical trials for rare, underserved, and low-survival cancers across Canada. The program provides grants of up to $2 million over five years.
  • Canadian Cancer SocietycoreStrategic or Co-development Partner · 22 April 2026Co-funder of the $25-million national clinical cancer research program supporting investigator-initiated clinical trials for rare and underserved cancers.
  • Terry Fox Research InstitutecoreStrategic or Co-development Partner · 22 April 2026Co-funder of the $25-million national clinical cancer research program. BioCanRx and TFRI have a history of co-funding translational cancer research initiatives.
  • Lotte & John Hecht Memorial FoundationminorStrategic or Co-development Partner · 22 April 2026Funder of the $25-million multi-partner clinical cancer research program.
  • Génome QuébecminorStrategic or Co-development Partner · 22 April 2026Funder of the $25-million multi-partner clinical cancer research program.
  • SickKids Garron Family Cancer CentreminorStrategic or Co-development Partner · 22 April 2026Partner funder of the $25-million multi-partner clinical cancer research program.
  • Kindred FoundationminorStrategic or Co-development Partner · 22 April 2026Partner funder of the $25-million multi-partner clinical cancer research program.
  • Childhood Cancer CanadaminorStrategic or Co-development Partner · 22 April 2026Partner funder of the $25-million multi-partner clinical cancer research program.
  • Institut du cancer de MontréalminorStrategic or Co-development Partner · 22 April 2026Partner funder of the $25-million multi-partner clinical cancer research program.
  • Ottawa Hospital Research Institute (OHRI)coreStrategic or Co-development PartnerBioCanRx is hosted by the Ottawa Hospital Research Institute. OHRI provides institutional infrastructure including the Biotherapeutics Manufacturing Centre, a world-class GMP facility with over 17 years of experience supporting BioCanRx projects.
  • BC CancercoreStrategic or Co-development PartnerNetwork partner providing the Conconi Family Immunotherapy Lab for CAR T cell manufacturing and the Genome Sciences Centre for plasmid manufacturing. Also hosts the Molecular and Cellular Immunology Core (MCIC).
  • McMaster UniversitycoreStrategic or Co-development PartnerNetwork partner providing research facilities including the McMaster Immunology Research Centre for recombinant virus production. Home to key BioCanRx investigators such as Dr. Brian Lichty.
  • Dalhousie UniversitycoreStrategic or Co-development PartnerNetwork partner institution with researchers engaged in BioCanRx-funded projects in cancer immunotherapy.
  • University of OttawacoreStrategic or Co-development PartnerNetwork partner and host university for BioCanRx-hosted OHRI. Key research collaborator in CAR T and viral immunotherapy programs.
  • University of British ColumbiacoreStrategic or Co-development PartnerNetwork partner institution with researchers at UBC and affiliated institutions contributing to BioCanRx-funded research.
  • The Hospital for Sick Children (SickKids)coreStrategic or Co-development PartnerNetwork partner providing pediatric clinical trial sites for CAR T therapy. Partner in the $25-million multi-partner clinical research program.
  • Queen's UniversitycoreStrategic or Co-development PartnerNetwork partner institution with researchers engaged in BioCanRx-funded cancer immunotherapy projects.
  • McGill University / Centre Hospitalier de l'Université de Montréal (CHUM)coreStrategic or Co-development PartnerNetwork partner institution contributing researchers and clinical expertise to BioCanRx-funded projects.
  • Carleton UniversitycoreStrategic or Co-development PartnerNetwork partner institution collaborating on BioCanRx-funded cancer immunotherapy research.
  • University Health Network (UHN)coreStrategic or Co-development PartnerNetwork partner hosting Princess Margaret Cancer Centre, a major adult clinical trial site for BioCanRx-funded CAR T trials. Dr. Marcus Butler leads Canadian-developed CAR T-cell therapy trials.
  • IRCM (Institut de recherches cliniques de Montréal)coreStrategic or Co-development PartnerHosts the Immunotherapy Monoclonal Antibody Platform (IMAP), a first-of-its-kind academic mAb facility in Canada established in 2020. Led by Dr. André Veillette, IMAP provides access to cutting-edge platforms for accelerating monoclonal antibody development for cancer treatment.
  • IRICoR (Institute for Research in Immunology and Cancer – Commercialization of Research)coreStrategic or Co-development PartnerNational leader in drug discovery and commercialization at Université de Montréal. Through a BioCanRx agreement, projects access IRICoR's scientific operations, IP strategies, business development, and industry collaboration support to move assets toward commercialization.
  • Turnstone Biologics Inc.coreStrategic or Co-development PartnerOttawa-based biotech spinout from BioCanRx network research (Bell, Lichty, Stojdl). BioCanRx supported early development of Turnstone's oncolytic viral immunotherapy platform, including the Ad-MG1-MAGEA3 product. Turnstone subsequently partnered with AbbVie in a major global collaboration. Recognized as one of the top 15 biotech start-ups in the world (FierceBiotech's 2017 Fierce 15).
  • Virica BiotechminorStrategic or Co-development PartnerOttawa-based biotech company that received timely BioCanRx investment to develop biomanufacturing tools that decrease the cost of manufacturing vaccines and biotherapeutics. CEO Dr. Jean-Simon Diallo is a network investigator at OHRI. Virica's innovations have enhanced biomanufacturing efficiency for network partners and have global commercialization potential.
  • IndspireminorStrategic or Co-development PartnerIndigenous-led charity providing mentorship for Indigenous students who receive BioCanRx Summer Studentships through the Rivers to Success program, offering one-on-one and group guidance from Indigenous peers and role models.
  • Algonquin CollegecoreStrategic or Co-development PartnerPartner with BioCanRx and the University of Ottawa in developing a micro-credential in good manufacturing practices (GMP) for biomanufacturing. Algonquin's college-level training complements university-level offerings in the CanPRIME program.
  • Let's Talk ScienceminorStrategic or Co-development PartnerNational organization providing hands-on science outreach. BioCanRx partners with Let's Talk Science to deliver cancer immunotherapy lessons, lab tours, and workshops in Canadian high schools, engaging over 10,000 students to date.
  • Alberta Cell Therapy Manufacturing Facility (ACTM)minorStrategic or Co-development PartnerGMP cell manufacturing facility in Edmonton that received technology transfer from BioCanRx network researchers (Levings Lab) for thymic Treg manufacturing through the Lab Exchange program.

Scale indicators14 records

Recent moves7 records

Expansion highlights6 records

BioCanRx competitors and assessment

Company assessment

Direct peers

  • Parker Institute for Cancer Immunotherapy (PICI): PICI is a US-based non-profit that funds and coordinates cancer immunotherapy research across leading academic centers, with a strong focus on translational science and clinical trials. PICI is BioCanRx's closest functional analog as a multi-institutional cancer immunotherapy research network.
  • Cancer Research Institute (CRI): CRI is a US non-profit that has funded immunology and cancer immunotherapy research for decades, supporting investigator-initiated translational grants and clinical trials. Like BioCanRx, CRI bridges academic discovery and clinical application in immuno-oncology.
  • Stand Up To Cancer (SU2C): SU2C is a major US charitable funder of translational cancer research, including multi-institutional "Dream Teams" focused on specific cancer types and modalities. Its model of funding collaborative translational teams closely parallels BioCanRx's network approach.
  • Ludwig Institute for Cancer Research: Ludwig is an international non-profit cancer research organization that operates across multiple centers, with significant translational and immunotherapy programs. It is comparable as a globally distributed, academically anchored cancer research network.
  • Terry Fox Research Institute: TFRI is a Canadian non-profit that funds pan-Canadian translational cancer research, including the recently co-funded $25M multi-partner clinical research program with BioCanRx. TFRI is both a peer and an active partner.
  • Cancer Research Society: CRS is a Canadian non-profit cancer research funder, lead partner in the $25M multi-partner clinical research program with BioCanRx. It is comparable as a Canadian cancer research funding organization, though with a broader scope beyond immunotherapy.

Others

  • Society for Immunotherapy of Cancer (SITC): SITC is a professional society that advances cancer immunotherapy through education, conferences, and scientific exchange. While not a funder like BioCanRx, SITC operates similar community/convening functions in immuno-oncology (e.g., annual meetings akin to Summit4CI).
  • Ottawa Hospital Research Institute: OHRI is the host institution for BioCanRx and provides core infrastructure including the Biotherapeutics Manufacturing Centre. As BioCanRx's institutional home and primary research partner, OHRI is functionally co-located rather than a competing entity.

Emerging players

  • Cellares: Cellares is an emerging cell therapy manufacturing automation company whose Cell Shuttle platform competes with the closed/automated point-of-care manufacturing concept that BioCanRx's CLIC network has built around. Both target decentralized, scalable CAR T production.

Broad incumbents

  • Lonza Cell & Gene Technologies: Lonza is a major global CDMO with extensive cell and gene therapy manufacturing capacity, including GMP viral vector and cell therapy production. As BioCanRx scales its BMC and CLIC manufacturing, Lonza is a global incumbent competitor for outsourced GMP services.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

BioCanRx social profiles

Digital presence

BioCanRx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BioCanRx leadership team

Management profile

Number of profiles

Profiles5 records

BioCanRx funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BioCanRx M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioCanRx

What does BioCanRx do?

BioCanRx is Canada's Immunotherapy Network — a not-for-profit research network that funds and actively supports the translation, manufacture, and adoption of cancer immunotherapies. The organization operates as a network-based platform providing competitive research funding, access to GMP biomanufacturing core facilities, training programs, and the CLIC Network for made-in-Canada CAR T-cell therapies, with the goal of moving promising discoveries from the lab into clinical trials.

Is BioCanRx a public or private company?

BioCanRx is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was BioCanRx founded?

BioCanRx was founded in 2014. It employs 11 to 50 people.

Where is BioCanRx based?

BioCanRx is headquartered in Ottawa, Canada, in the North America region.

How does BioCanRx make money?

Two revenue lines are on record. Federal Government Research Funding is the primary driver. The others are partner and Industry Contributions.

Who are BioCanRx's main competitors?

Direct peers on record are Parker Institute for Cancer Immunotherapy (PICI), Cancer Research Institute (CRI), Stand Up To Cancer (SU2C), Ludwig Institute for Cancer Research, Terry Fox Research Institute and Cancer Research Society. Others are Society for Immunotherapy of Cancer (SITC) and Ottawa Hospital Research Institute. Cellares is listed as an emerging player. Lonza Cell & Gene Technologies is listed as a broad incumbent.

Does BioCanRx have an API?

No public API is recorded for BioCanRx.

What industry is BioCanRx in?

BioCanRx's product category is Cancer Immunotherapy Research Network. Its primary akta.pro industry code is HLAAAKAF, Process Development & Tech Transfer Services (upstream/downstream), with a secondary code of HLAIALAF, Translational Medicine & Biomarkers. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NewswireMajor $25-Million Investment Propels New Era of Clinical Cancer Research in CanadaThe Cancer Research Society, with the Canadian Cancer Society and Terry Fox Research Institute, launched a national program to fund investigator-initiated clinical trials across Canada. The $25-million investment provides grants up to $2 million over five years for trials addressing rare cancers, early detection, and prevention.YahooMajor $25-Million Investment Propels New Era of Clinical Cancer Research in CanadaThe Cancer Research Society, in partnership with the Canadian Cancer Society and the Terry Fox Research Institute, has launched a first-of-its-kind national program to support investigator-initiated clinical trials across Canada, backed by a $25-million multi-partner investment. The initiative will provide grants of up to $2 million over five years to fund independent clinical trials focused on rare, underserved, and low-survival cancers, addressing a critical gap in funding for research not sponsored by the pharmaceutical industry. The program brings together major cancer research funders including the Lotte & John Hecht Memorial Foundation, Génome Québec, SickKids Garron Family Cancer Centre, Kindred Foundation, Childhood Cancer Canada, BioCanRx, and Institut du cancer de Montréal to accelerate the translation of discoveries into patient care.NewswireGovernment of Canada invests in cutting-edge research and the next generation of scientistsThe Government of Canada announced an investment of up to $171.6 million in five science and research organizations through the Strategic Science Fund. The funding, awarded via a competitive process, supports entities including Actua, ArcticNet Inc., BioCanRx, CASC, and the Stem Cell Network for projects ranging from health solutions to climate change research.BiocanrxBioCanRx Welcomes Strategic Science Fund InvestmentThe Canadian government announced support for 24 third-party science and research organizations, including BioCanRx, under the new Strategic Science Fund. This investment aims to sustain BioCanRx's project pipeline and facilitate life-saving clinical trials for cancer patients using domestic immunotherapies.GlobeNewswireHarper Government Invests in New Cancer Research NetworkBioCanR X, a cancer research network, received $25 million over five years from Industry Canada. The funding supports collaborative research to develop novel Canadian therapies, including patient outreach and clinical testing. The network aims to make Canada more competitive in biotherapeutics and reduce cancer costs.